Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mycophenolic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 known ✓ | P12268 | 20/20 | 1.00 |
| ▸ | IMPDH1 known ✓ | P20839 | 10/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | UGT2B7 | P16662 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.79 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.79 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.79 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.79 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.79 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.79 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.79 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.79 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mycophenolic Acid SCHEMBL1657813 | 1.00 | IMPDH2 (1.00) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| Mycophenolic Acid SCHEMBL29645054 | 1.00 | IMPDH2 (1.00) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| Mycophenolic Acid SCHEMBL2514376 | 1.00 | IMPDH2 (1.00) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| Mycophenolic Acid SCHEMBL29380425 | 1.00 | IMPDH2 (1.00) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| Mycophenolic Acid SCHEMBL4549 | 1.00 | IMPDH2 (1.00) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| Mycophenolic Acid SCHEMBL5259872 | 1.00 | IMPDH2 (1.00) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| Mycophenolic Acid SCHEMBL1230249 | 1.00 | IMPDH2 (1.00) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| Mycophenolic Acid SCHEMBL6502425 | 0.99 | IMPDH2 (0.98) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| Mycophenolic Acid SCHEMBL3652377 | 0.99 | IMPDH2 (0.98) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| Mycophenolic Acid SCHEMBL1657815 | 0.99 | IMPDH2 (0.98) | IMPDH2IMPDH1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000819-A1 | METHODS FOR ENHANCING CYTOTOXIC CANCER THERAPY THROUGH MODULATION OF PURINE BIOSYNTHESIS PATHWAYS | UNIV NORTHWESTERN (US) | 2024-01-04 | — | — | US | claimed |
| US-20210145855-A1 | METHODS FOR ENHANCING CYTOTOXIC CANCER THERAPY THROUGH MODULATION OF PURINE BIOSYNTHESIS PATHWAYS | NORTHWESTERN UNIVERSITY | 2021-05-20 | — | — | US | claimed |
| US-20240000819-A1 | METHODS FOR ENHANCING CYTOTOXIC CANCER THERAPY THROUGH MODULATION OF PURINE BIOSYNTHESIS PATHWAYS | UNIV NORTHWESTERN (US) | 2024-01-04 | — | — | US | disclosed |
| WO-2024002112-A1 | METHOD FOR TREATING FELINE CORONAVIRUS OR CALICIVIRUS INFECTION | 苏州旺山旺水生物医药股份有限公司 | 2024-01-04 | — | — | WO | disclosed |
| US-11786542-B2 | Methods for enhancing cytotoxic cancer therapy through modulation of purine biosynthesis pathways | NORTHWESTERN UNIVERSITY (US) | 2023-10-17 | — | — | US | disclosed |
| US-20210145855-A1 | METHODS FOR ENHANCING CYTOTOXIC CANCER THERAPY THROUGH MODULATION OF PURINE BIOSYNTHESIS PATHWAYS | NORTHWESTERN UNIVERSITY | 2021-05-20 | — | — | US | disclosed |
| CN-110376386-A | A kind of preparation method detecting the test strips of mycophenolic acid, kit and test strips | 北京丹大生物技术有限公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-106942230-B | Purposes of the mycophenolic acid class compound in prevention and treatment smut of sugarcane | 华南农业大学 | 2019-09-10 | — | — | CN | disclosed |
| CN-106942230-A | Purposes of the mycophenolic acid class compound in smut of sugarcane is prevented and treated | 华南农业大学 | 2017-07-14 | — | — | CN | disclosed |
| EP-1740564-A2 | PROCESS FOR PREPARATION OF MYCOPHENOLIC ACID AND ESTER DERIVATIVES THEREOF | Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság (HU) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105768-A2 | PROCESS FOR PREPARATION OF MYCOPHENOLIC ACID AND ESTER DERIVATIVES THEREOF | TEVA GYÓGYSZERGYÁR ZÀRTKÖRUEN MUKÖDO RÈSZVÈNYTÀRSASÀG (HU) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786542-B2 | Methods for enhancing cytotoxic cancer therapy through modulation of purine biosynthesis pathways | IMPDH1, IMPDH2, AMPD3 | IMPDH2 2/4885IMPDH1 1/4885KDM4E 2591/4885 |
| US-20210145855-A1 | METHODS FOR ENHANCING CYTOTOXIC CANCER THERAPY THROUGH MODULATION OF PURINE BIOSYNTHESIS PATHWAYS | IMPDH1, IMPDH2, AMPD3 | IMPDH2 2/4885IMPDH1 1/4885KDM4E 2591/4885 |
| US-20240000819-A1 | METHODS FOR ENHANCING CYTOTOXIC CANCER THERAPY THROUGH MODULATION OF PURINE BIOSYNTHESIS PATHWAYS | IMPDH1, IMPDH2, AMPD3 | IMPDH2 2/4885IMPDH1 1/4885KDM4E 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.